For millions of women and individuals assigned female at birth, the diagnosis of Polycystic Ovary Syndrome (PCOS) often marks the beginning of a long and frequently confusing medical journey. For years, the name itself has been a point of contention among clinicians and patients alike, as it suggests the condition is primarily a problem of the ovaries. However, a growing movement within the medical community is calling for a fundamental shift in how the condition is named and understood, proposing a transition toward a designation that reflects its systemic, metabolic nature.
The proposal to rename the condition—often referred to in Spanish-speaking medical circles as SOMP (Síndrome Metabólico de Ovario Poliquístico) or Metabolic Polycystic Ovary Syndrome in English—is not merely a semantic exercise. It is a clinical intervention designed to correct a limited denomination that may lead to diagnostic delays and incomplete treatment plans. By centering the “metabolic” aspect of the syndrome, health professionals aim to shift the focus from reproductive organs to the endocrine and metabolic systems that drive the disorder.
As a physician and journalist, I have seen how a name can shape the trajectory of patient care. When a patient is told they have “polycystic ovaries,” the mental image is often one of cysts on an organ. This narrows the conversation to fertility and menstruation, often overlooking the critical risks of insulin resistance, type 2 diabetes, and cardiovascular disease. The push for a PCOS name change is about expanding the clinical lens to ensure that metabolic health is prioritized from the moment of diagnosis.
This shift acknowledges that while the ovaries are often affected, they are frequently the site of the symptoms rather than the sole source of the problem. The underlying driver is often a complex interplay of hormonal imbalances and metabolic dysfunction that affects the entire body, from the skin and hair to the heart and mind.
The Misnomer of “Polycystic”
The most significant argument for renaming the syndrome is that the term “polycystic” is clinically inaccurate for a substantial portion of the affected population. In medical terms, the “cysts” seen on an ultrasound are not actually tumors or traditional cysts, but rather underdeveloped follicles—small sacs of fluid that contain eggs that failed to mature and release during ovulation.
Under the widely accepted Rotterdam Criteria, which are used globally to diagnose the condition, a patient only needs to meet two of three specific criteria: irregular or absent menstrual periods (ovulatory dysfunction), clinical or biochemical signs of high androgen levels (hyperandrogenism), and the presence of polycystic ovaries on an ultrasound. So that a person can be diagnosed with PCOS without ever having “polycystic” ovaries.
When the name of the condition emphasizes the ovaries, patients who do not exhibit polycystic morphology on an ultrasound may feel their diagnosis is invalid, or doctors may overlook the diagnosis entirely. By moving toward a “metabolic” designation, the medical community acknowledges that the systemic endocrine dysfunction is the primary driver, regardless of whether the ovaries appear polycystic on a scan.
The Metabolic Core: Insulin and Androgens
At the heart of the proposal for Metabolic Polycystic Ovary Syndrome is the role of insulin resistance. A significant percentage of people with PCOS experience insulin resistance, a condition where the body’s cells do not respond effectively to insulin, leading the pancreas to produce more of the hormone to compensate. This state of hyperinsulinemia creates a cascading effect throughout the body.
Excess insulin does more than affect blood sugar; it acts directly on the ovaries, stimulating them to produce excess androgens (male-type hormones like testosterone). This hormonal surge is what disrupts ovulation, leading to irregular periods and infertility. It also causes the physical symptoms many patients find most distressing, such as hirsutism (excess hair growth on the face and chest), severe acne, and androgenic alopecia (thinning of the scalp hair).
The metabolic nature of the disorder extends far beyond the reproductive system. According to the World Health Organization, the condition is closely linked to an increased risk of obesity, hypertension, and dyslipidemia. Without a metabolic-first approach to treatment, patients are at a significantly higher risk of developing type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) later in life.
Renaming the condition to emphasize its metabolic roots encourages physicians to screen for these comorbidities early. Rather than focusing solely on hormonal contraceptives to regulate periods, a metabolic framework prioritizes glycemic control, nutritional intervention, and cardiovascular monitoring as primary pillars of care.
The Psychosocial Impact and Mental Health
The proposal to rename the syndrome also seeks to validate the systemic psychological toll of the disorder. For too long, the mental health struggles associated with PCOS have been treated as secondary reactions to physical symptoms—such as depression resulting from infertility or anxiety caused by acne. However, emerging evidence suggests a more complex, bidirectional relationship between metabolic dysfunction and mental health.
Chronic inflammation and insulin instability can directly affect brain chemistry, contributing to mood swings, depression, and anxiety. When the condition is framed as a “syndrome of the ovaries,” these systemic neurological and psychological effects are often marginalized. A metabolic designation recognizes that the disorder affects the entire organism, including the brain.
the psychological burden of a “misnamed” condition can lead to “medical gaslighting,” where patients feel their systemic symptoms—such as extreme fatigue or brain fog—are being dismissed because they do not fit the traditional “polycystic” narrative. A more inclusive and accurate name provides a framework for patients to discuss their holistic health with their providers.
What This Change Means for Diagnosis and Treatment
If the transition to a metabolic-centered name becomes the global standard, the approach to patient care will likely evolve in several key ways:
- Earlier Metabolic Screening: Instead of waiting for the onset of obesity or diabetes, clinicians would likely implement early screening for insulin resistance and glucose intolerance as a standard part of the initial diagnosis.
- Multidisciplinary Care Teams: The shift would move the patient away from the sole care of a gynecologist and toward a team that includes endocrinologists, registered dietitians, and mental health professionals.
- Diversified Treatment Goals: While regulating the menstrual cycle remains important, the primary goal would shift toward metabolic stability, reducing the long-term risk of cardiovascular disease and metabolic syndrome.
- Patient Empowerment: By understanding the “why” behind their symptoms (e.g., “my insulin is driving my androgen production” rather than “my ovaries are cysts”), patients can take more targeted and effective control of their lifestyle interventions.
The current medical landscape is seeing a gradual adoption of this mindset, even before the official nomenclature changes in all textbooks. Many leading endocrine societies are already emphasizing the “metabolic phenotype” of the syndrome, recognizing that the “polycystic” label is an outdated remnant of early ultrasound technology rather than a comprehensive description of the disease.
Key Takeaways for Patients and Providers
- The Name is a Misnomer: “Polycystic” refers to follicles, not true cysts, and many people with the syndrome have no polycystic ovaries at all.
- Metabolism is Central: Insulin resistance is a primary driver of the hormonal imbalances that cause the symptoms of the syndrome.
- Systemic Risks: The condition increases the risk of type 2 diabetes, hypertension, and cardiovascular issues, making metabolic monitoring essential.
- Mental Health Matters: Anxiety and depression are not just reactions to the condition but are often linked to the systemic nature of the endocrine disorder.
- Treatment is Holistic: Effective management requires a combination of endocrine support, nutritional changes, and mental health care, not just reproductive regulation.
The Path Forward
The movement to rename Polycystic Ovary Syndrome to reflect its metabolic nature is a reflection of a broader trend in medicine: the move toward precision medicine and holistic patient-centered care. By stripping away a limiting and inaccurate label, the medical community can reduce stigma, improve diagnostic accuracy, and ultimately save lives by preventing the metabolic complications that often follow an incomplete diagnosis.
While the term PCOS remains the most recognized name globally, the rise of the “metabolic” framework signals a new era of understanding. For the patient, this means a shift from being told “something is wrong with your ovaries” to “we are managing your systemic metabolic health.”
The next major checkpoint for this transition will be the upcoming updates to international clinical practice guidelines from major endocrine and gynecological associations, which are expected to further integrate metabolic markers into the primary diagnostic criteria. As these guidelines evolve, we can expect the nomenclature to follow suit, ensuring that the name of the condition finally matches the reality of the disease.
Do you or a loved one live with PCOS? Have you found that the “polycystic” label didn’t fit your experience? We invite you to share your story and thoughts in the comments below to help foster a more inclusive conversation about women’s metabolic health.